MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.840
+0.020
+1.10%
Closed 16:00 07/28 EDT
OPEN
1.774
PREV CLOSE
1.820
HIGH
1.870
LOW
1.774
VOLUME
97.72K
TURNOVER
--
52 WEEK HIGH
4.360
52 WEEK LOW
1.720
MARKET CAP
24.90M
P/E (TTM)
-1.2438
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19)
Benzinga · 07/20 12:19
Stocks That Hit 52-Week Lows On Monday
  Stocks That Hit 52-Week Lows On Monday Monday morning, 285 companies reached new 52-week lows.
Benzinga · 07/19 14:04
Phio Pharmaceuticals Scheduled to Participate in a Fireside Chat with H.C. Wainwright on July 12th
/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it will pa...
PR Newswire - PRF · 07/07 20:30
Phio Pharmaceuticals Reschedules Fireside Chat Hosted by H.C. Wainwright for July 12th
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it has rescheduled the Com...
PR Newswire · 06/22 15:04
Is Phio Pharmaceuticals Corp. (PHIO) A Good Stock To Buy?
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain ex...
Insider Monkey · 06/14 20:09
10 Biggest Price Target Changes For Monday
Needham raised OrthoPediatrics Corp. (NASDAQ: KIDS) price target from $70 to $77. Vertex Pharmaceuticals shares rose 0.2% to close at $63.51 on Friday.
Benzinga · 06/14 13:31
Phio Pharmaceuticals Scheduled to Participate in Two Upcoming Investor Events in June
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its Chief Executive Office...
PR Newswire · 06/14 12:00
HC Wainwright & Co. Maintains Buy on Phio Pharmaceuticals, Raises Price Target to $6
HC Wainwright & Co. analyst Vernon Bernardino maintains Phio Pharmaceuticals (NASDAQ:PHIO) with a Buy and raises the price target from $4 to $6.
Benzinga · 06/14 10:24
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PHIO. Analyze the recent business situations of Phio Pharmaceuticals Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PHIO stock price target is 6.00 with a high estimate of 6.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 23
Institutional Holdings: 1.15M
% Owned: 8.52%
Shares Outstanding: 13.53M
TypeInstitutionsShares
Increased
6
162.03K
New
7
87.00K
Decreased
1
38.20K
Sold Out
2
17.68K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.42%
Pharmaceuticals & Medical Research
+1.82%
Key Executives
Chairman/Director
Robert Bitterman
President/Chief Executive Officer/Chief Operating Officer
Gerrit Dispersyn
Other
John Barrett
Director
Geert Cauwenbergh
Independent Director
H. Paul Dorman
Independent Director
Jonathan Freeman
Independent Director
Curtis Lockshin
No Data
  • All
  • Financials
  • Insiders
More
About PHIO
Phio Pharmaceuticals Corp, formerly RXi Pharmaceuticals Corporation, is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) (sd-rxRNA) therapeutic platform. The Company’s focuses on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets, or to be used in immunotherapy following intratumoral injection. The Company’s pipeline include RXI-762 and RXI-804. Its sd-rxRNA compounds are designed to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. The Company is developing RXI-762 for the treatment of Melanoma, Ovarian cancer and other indications. RXI-804 is an sd-rxRNA compound that is designed to suppress the expression of immune checkpoint protein, TIGIT.

Webull offers kinds of Phio Pharmaceuticals Corp stock information, including NASDAQ:PHIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PHIO stock methods without spending real money on the virtual paper trading platform.